Supernus Pharmaceuticals, Inc. $SUPN Shares Acquired by Signaturefd LLC

Signaturefd LLC raised its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 12,566.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,754 shares of the specialty pharmaceutical company’s stock after buying an additional 66,227 shares during the quarter. Signaturefd LLC owned about 0.11% of Supernus Pharmaceuticals worth $2,873,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of SUPN. BlackRock Inc. purchased a new stake in Supernus Pharmaceuticals in the 2nd quarter worth $434,871,000. Bank of America Corp DE increased its holdings in shares of Supernus Pharmaceuticals by 37.2% in the first quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock worth $36,918,000 after purchasing an additional 193,479 shares during the last quarter. Ashford Capital Management Inc. increased its holdings in shares of Supernus Pharmaceuticals by 5.4% in the first quarter. Ashford Capital Management Inc. now owns 645,381 shares of the specialty pharmaceutical company’s stock worth $33,360,000 after purchasing an additional 32,843 shares during the last quarter. Rice Hall James & Associates LLC purchased a new stake in shares of Supernus Pharmaceuticals in the second quarter worth about $22,800,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Supernus Pharmaceuticals in the second quarter worth about $17,553,000.

Analysts Set New Price Targets

Several analysts have recently issued reports on SUPN shares. Wall Street Zen cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Zacks Research lowered Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, October 5th. Cantor Fitzgerald upped their price objective on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, September 21st. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $63.00.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock opened at $40.70 on Monday. Supernus Pharmaceuticals, Inc. has a twelve month low of $37.54 and a twelve month high of $59.68. The stock has a fifty day simple moving average of $43.11 and a two-hundred day simple moving average of $46.03. The stock has a market capitalization of $2.37 billion, a price-to-earnings ratio of -21.20, a P/E/G ratio of 1.20 and a beta of 0.55.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). The company had revenue of $219.06 million for the quarter, compared to the consensus estimate of $205.31 million. Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. Supernus Pharmaceuticals’s revenue for the quarter was up 32.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.40 EPS. Research analysts predict that Supernus Pharmaceuticals, Inc. will post 1.79 EPS for the current fiscal year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.